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Although many cytotoxic drugs have been tested as single agents
in patients with advanced non-small-cell lung cancer (NSCLC),
only a few (cisplatin, vindesine, mitomycin, ifosfamide, vinblas-
tine, irinotecan and taxanes) have produced response rates greater
than 15% (Ihde, 1992). Currently, cisplatin is a standard agent
used in combination therapies for NSCLC. Results of a random-
ized trial (Rapp et al, 1988) and a recent meta-analysis from 52
randomized trials demonstrated that cisplatin-containing regimens
improve, albeit modestly, survival benefit compared to best
supportive care in patients with advanced NSCLC (NSCLC
Collaborative Group, 1995). New agents that have become avail-
able in the 1990s have consistently demonstrated significant
anti-tumour activity and encouraging toxicity profiles, while
incorporating different mechanisms of anti-tumour action. One
such agent, gemcitabine, is an antimetabolite structurally similar
to cytarabine (ARA-C), but possesses a unique mechanism of
action that exerts a much wider range of anti-tumour activity in
vitro (Hertel et al, 1990; Lund et al, 1993). Gemcitabine mimics
the structure of the naturally occurring nucleoside, deoxycytidine,
and thus is inserted into the nucleoside sites of DNA. The addi-
tional nucleoside in the DNA strand masks gemcitabine from
DNA repair mechanisms that might excise it. This ‘masked chain’
effect allows gemcitabine to exert a wide spectrum of anti-tumour
activity against human neoplasms, such as lung, ovarian, and
pancreatic cancers (Gatzemeier et al, 1996; Rothenberg et al,
1996).
In phase II trials performed in chemo-naïve patients with
NSCLC, first-line treatment with gemcitabine (1000–1250 mg m–2)
produced consistent and reproducible response rates of approxi-
mately 20–23% (Abratt et al, 1994; Anderson et al, 1994;
Gatzemeier et al, 1996). In all of these studies, which used the
gemcitabine weekly regimen (intravenous infusion over 30 min
given weekly for 3 weeks every 28 days), the toxicity profile was
modest and characterized by mild leukopenia and thrombocyto-
penia, and other negligible toxic effects, making it an acceptable
choice for combination therapy. In addition, response rates and
toxicity profiles of gemcitabine are similar in pretreated and
untreated patients with pancreatic cancer (Rothenberg et al, 1996)
and lung cancer (Crinó et al, 1997a). This phase II trial was
conducted to determine the objective tumour response rate and
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Summary The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell
lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity
profile of single-agent gemcitabine in pretreated patients with NSCLC. Patients with histological evidence of advanced NCSLC stage IIIB or
IV; at least one prior chemotherapy regimen including a platinum or taxane analogue; an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2; clinically measurable disease; adequate bone marrow reserve; and adequate renal function; received 1000 mg
m–2 gemcitabine administered over 30 min on days 1, 8 and 15 of a 28-day cycle defined as 3 weekly treatments followed by 1 week of rest.
Twenty-nine patients were evaluated for efficacy and 32 for toxicity. One patient achieved a complete response and five patients had a partial
response resulting in a total response rate of 20.6% (95% confidence interval (CI) 6–34). Median response duration was 7 months (range
4–11 months). Twelve (41%) patients reached stable disease after two cycles of therapy and 11 (38%) patients had disease progression.
Median progression-free survival time was 3 months and median overall survival time was 5.5 months. Toxicity was generally mild (grades
0–2). Severe (grade 3 or 4) haematological toxicities included grade 3 anaemia in one patient and grade 3 thrombocytopenia in two patients.
Severe non-haematological toxicities included one patient each with grade 3 liver transaminase elevations, nausea/vomiting and diarrhoea.
This study confirms the activity and safety of single-agent gemcitabine in pretreated patients with advanced NSCLC who are refractory or
sensitive to first-line therapy. © 1999 Cancer Research Campaign
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toxicity profile of gemcitabine used as a single agent in pretreated
patients with NSCLC.
PATIENTS AND METHODS
The protocol was approved by the local Ethics Committees at
participating centres and patients signed informed consent prior to
inclusion. Patients were included in the study if they had histolog-
ical evidence of advanced stage IIIb or IV not amenable to curative
surgery or radiation; at least one prior chemotherapy regimen
including a platinum or taxane analogue; an Eastern Cooperative
Oncology Group (ECOG) performance status of 0–2; clinically
measurable disease defined as bidimensionally measurable
lesions; adequate bone marrow reserves; and adequate hepatic and
renal function. Patients received 1000 mg m–2 gemcitabine admin-
istered by intravenous infusion over 30 min on days 1, 8 and 15 of
a 28-day cycle defined as 3 weeks of treatment followed by 1 week
of rest. Treatment was continued until progressive disease or
unacceptable toxicity occurred with no maximum number of
cycles imposed on the patients. Premedication and prophylactic
antiemetic therapy was left to the discretion of the investigator.
Dose adjustments and omissions were scheduled for patients
experiencing grade 3 or 4 haematological toxicities according to
the guidelines shown in Table 1.
All patients who received at least one cycle of gemcitabine and
met protocol criteria were included in the efficacy analyses. All
patients who received at least one gemcitabine dose and met all
protocol entry criteria were included in the safety analyses.
Survival was measured from the day of the first dose until the day
of death. Progression-free survival was measured from the first
day of treatment until the day of progressive disease or discontinu-
ation of treatment. Objective tumour response rates and survival
times were computed and survival curves were generated using
the Kaplan–Meier method. Toxicity and tumour response were
assessed using World Health Organization (WHO) criteria.
RESULTS
A total of 34 patients were registered and 33 patients entered the
study and received gemcitabine at 13 Argentinean centres between
December 1996 and Februrary 1998 (one patient withdrew from
protocol before the start of gemcitabine and was lost to follow-up).
Thirty-two patients (23 males and nine females) with a median age
of 58 years were included in the analyses (32 evaluable for toxicity
and 29 for efficacy). Among these patients, all had stage IIIb (15
patients) or stage IV (17 patients) disease, and most had histolog-
ical evidence of adenocarcinoma (20 patients) and received at least
one prior chemotherapy regimen containing a platinum or taxane
analogue. Patients’ characteristics are presented in Table 2.
Patients received a total of 102 cycles with a median of 3 cycles
per patient (range 1–8 cycles).
Of the 33 patients who entered the study and actually received
the drug, four were considered ineligible for the efficacy analyses:
three patients had prior radiotherapy on the only site of measurable
disease, and one patient received concomitant treatment with
carboplatin. This last patient was also excluded from toxicity
analysis. Response rates are presented in Table 3. One patient
achieved a complete response (adrenal metastasis as the only site
of disease, in a patient progressing after prior chemotherapy with
carboplatin+etoposide) and five patients had a partial response
resulting in a total response rate of 20.6% (95% confidence
interval (CI) 6–34). The median response duration was 7 months
(range 4–11 months). Twelve (41%) patients reached stable
disease after two cycles of therapy and 11 (38%) patients had
disease progression; disease progression occurred in the first cycle
for two patients. External validation of claimed responses was not
performed.
Table 1
Leucocytes ´ mm3 Platelets ´ mm3 Dose given
> 3.000 y > 100.000 100%
1.500–3.000 ó 50.000–100.000 75%
< 1.500 ó < 50.000 Hold
Table 2 Patient characteristics
Characteristic
Total registered 34
Total entered (received drug) 33
Total evaluable 32
Efficacy 29
Safety 32
Number males 23
Number females 9
Median age 58
ECOG performance status:
05
11 8
25
Unspecified 4
Stage
Recurrent IIIB 15
IV 17
Histology
Adenocarcinoma 20
Squamous 9
Large cell 3
Evaluable disease pattern
Lung 25
Nodes 9
Liver 6
Adrenal 3
Bone 2
Skin 2
Prior therapy
Cisplatin/carboplatin + etoposide 13
Cisplatin/carboplatin + paclitaxel 8
Cisplatin + vinorelbine 4
Other cisplatin combinations 2
Taxanes (single agents) 2
Other taxane combinations 5
Radiotherapy 5
ECOG = Eastern Cooperative Oncology Group.
Table 3 Response rate
Patients evaluable 29 
Complete response 1 (3.4%)
Partial response 5 (17.2%)
Total objective response rate 20.6%
Stable disease 12 (41.4%)
Progressive disease 11 (37.9%)848 M Van Kooten et al
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Responders represented patients across a wide age group (56–76
years), a range of performance levels (0–2) and a range of prior
chemotherapy regimens including single-agent docetaxel in one
patient, platinum/etoposide in three patients and carboplatin/
paclitaxel combination in two patients (Table 4). All but one of the
responders had adenocarcinoma. The disease among responders
was predominantly in the lung and mediastinal nodes, but was also
present in the adrenal gland (two patients) and the liver (metastasis
in one patient).
Survival curves are shown in Figure 1. Median progression-free
survival time was 3 months (95% CI 2.7–5.4 months) and median
overall survival time was 5.5 months (95% CI 4.2–7.3 months).
Survival curves show 43% of patients alive at 6 months and 29%
alive at 1 year. Twenty-four patients had died as of June 1998.
One of the patients excluded from the efficacy analyses because
of concomitant treatment with carboplatin, was also excluded from
the toxicity analyses. Thus, 32 patients were evaluated for toxicity.
Toxicity was generally mild (grades 0–2). Laboratory and non-
laboratory toxicities are presented in Tables 5 and 6 respectively.
Severe (grade 3 or 4) haematological toxicities included grade 3
anaemia in one patient and grade 3 thrombocytopenia in two
patients. Severe non-haematologic toxicities included one patient
each with grade 3 liver transaminase elevations, nausea/vomiting
and diarrhoea. Clinically significant asthenia was noted in three
patients. Eleven doses (out of 306 planned injections) were
omitted, ten doses were reduced and seven doses were delayed
primarily due to leukopenia and thrombocytopenia toxicities.
DISCUSSION
Gemcitabine is an active agent against advanced NSCLC when
used alone or as part of a combination regimen. In this study and in
other studies in pretreated patients (Crinó et al, 1997a; Guerra et
al, 1997; Piazza et al, 1997; Rosvold et al, 1998), single-agent
gemcitabine as second-line therapy produced an overall response
rate of approximately 20%, which is similar to response rates
observed in single-agent gemcitabine studies in untreated patients,
who are not cross-resistant with other agents commonly used in
Table 4 Chemotherapy sensitivity of responders (n = 6)
Patient Initial regimen Response Response to
number to 1st line Gemcitabine
1 Docetaxel Complete response PR
2 Cisplatin/Paclitaxel Minor response PR
3 Cisplatin/Etoposide Stable disease PR
4 Carboplatin/Etoposide Relapse within 2 months PR
(adjuvant)
5 Carboplatin/Paclitaxel Progressive disease PR
6 Carboplatin/Etoposide Progressive disease CR
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Figure 1 Gemcitabine in pretreated patients with NSCLC. Progression-free and overall survival
Table 5 WHO haematologic toxicity number (%) of patients
Maximum WHO grade attained n = 32
Toxicity 0–1 2 3 4
Anaemia 29 (91) 2 (6) 1 (3) 0
Leukopenia 28 (88) 4 (13) 0 0
Thrombocytopenia 28 (88) 2 (6) 2 (6) 0
WHO = World Health Organization.
Table 6 WHO non-haematologic toxicity Number (%) of patients
Maximum WHO grade attained n = 32
Toxicity 0–1 2 3 4
Liver transaminasesa 30 (94) 1 (3) 1 (3) 0
Creatinine 32 (100) 0 0 0
Alopecia 31 (97) 1 (3) 0 0
Nausea/vomiting 30 (94) 1 (3) 1 (3) 0
Skin rash 30 (94) 2 (6) 0 0
Peripheral oedema 32 (100) 0 0 0
Dyspnoea/chest pain 32 (100) 0 0 0
Asthenia 29 (91) 3 (9) 0 0
Phlebitis 30 (94) 2 (6) 0 0
Diarrhoea 30 (94) 1 (3) 1 (3) 0
Mucositis 31 (97) 1 (3) 0 0
WHO = World Health Organization. a Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST).Gemcitabine in previously treated NSCLC patients 849
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this setting. Given an appropriate regimen, gemcitabine is consid-
ered to interact synergistically with cisplatin to enhance its cyto-
toxicity as evidenced by the clinical results observed in first-line
treatment with gemcitabine–cisplatin combination regimens
producing response rates of 30–50% (Abratt et al, 1997; Crinó et
al, 1997b; Einhorn, 1997; Shepherd et al, 1997). In patients who
are unable to tolerate the greater toxicity associated with cisplatin-
based therapies, who are either sensitive (prior responders) or
refractory (prior non-responders) to first-line therapy, single-agent
gemcitabine with its proven activity and modest side-effects offers
an alternative to combination therapy. In this study, patients with
advanced disease who were refractory or sensitive to first-line
therapy (including taxane and platinum analogues) (Table 4), and
who represented a wide age group (56–76 years), a range of
performance levels (0–2), and a range of prior chemotherapy regi-
mens had excellent response rates and tolerable toxicities to gem-
citabine therapy. In addition, the toxicity profile in this study was
similar to those observed in other single-agent gemcitabine studies
in untreated patients with NSCLC, as was previously reported by
Crinó et al (1997a) and Rothenberg et al (1996) for second-line
lung and pancreas cancer patients.
Although not formally evaluated in this study, symptomatic
improvement might be as important an end point as objective
response in this patient population. In a single-agent gemcitabine
study in pretreated patients with NSCLC, symptomatic benefit
was evaluated and reported as significant (Guerra et al, 1997),
although the value of gemcitabine as second-line therapy
compared to that of best supportive care has yet to be determined
in a randomized trial in pretreated patients.
Given the fact that the benefits of first-line platinum-based
chemotherapy are modest, indications for second-line therapy are
even more arguable. However, increasing numbers of patients with
relapsed NSCLC, but otherwise in good condition (PS 0–1), seek
second-line therapy, even in the absence of proven benefit.
Few agents have shown consistent activity in the setting of
platinum-pretreated NSCLC, docetaxel being the most active so
far studied (Fossella et al, 1997); other agents reported reveal
contradictory data.
Gemcitabine, based on the available data, shows at least a degree
of activity similar to docetaxel and might prove useful also in the
presence of taxane-resistant NSCLC. One of the potential advan-
tages of gemcitabine would be represented by its minimal general
toxicity, and in particular, the absence of overlapping toxicities
with platinum and taxanes such as neurotoxicity and alopecia.
In conclusion, this study confirms the activity of gemcitabine
administered as a single agent in pretreated patients. The effective-
ness and mild toxicity profile of gemcitabine encourages its use in
patients with locally advanced or metastatic NSCLC as single
therapy or in combination with other agents in first-line treatment
and as a single agent for second-line patients who relapse or
progress after platinum- or taxane-based chemotherapy.
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